We recently compiled a list of the 12 AI Stocks Making Headlines: Latest News and Ratings. In this article, we are going to take a look at where IGC Pharma, Inc. (NYSEAMERICAN:IGC) stands against the other AI stocks.
Mark Mahaney, Senior Managing Director at Evercore ISI, discussed how AI is reshaping the tech industry with Bloomberg’s Alix Steel and Paul Sweeney at the Bloomberg Invest conference in New York City. Amid a market downturn, with the Nasdaq 100 now trading below its 200-day moving average, Mahaney cited two reasons for the tech part of the sell-off.
First, he said the tech sector has witnessed phenomenal outperformance in the last two and a half years. Therefore, a mean reversion scenario implies that stocks that have significantly outperformed will eventually face downward adjustments. The second reason that he quoted is the tariff issues upending businesses, depending on how well-hedged they are.
READ NOW: 10 AI Stocks Making Big Moves Today and 10 AI Stocks to Watch Now
“Equity valuations have been very elevated and there’s been yellow flags all over the horizon given moves to cut government spending. Now on top of that, we have all this rhetoric around tariffs.”
-Ben McMillan, chief investment officer at IDX Insights in Tampa, Florida.
It’s not only the tech stocks that are going to be affected by the tariffs issue. According to McMillan, Wall Street is really concerned. “The likelihood of tariffs will lead to higher prices and therefore lower spending.”
“The fear here is that it’s going to slow (economic) growth. And when you have a slowdown in economic conditions, it’s a situation where banks specifically make less money because fewer goods and services are traveling through the economy.”
-Adam Sarhan, CEO of 50 Park Investments in New York.
Market volatility and tariff concerns may be shaping the tech sector, but another key factor has been influencing investor sentiment. When asked about a misconception in the AI world, Mahaney pointed to DeepSeek, stating that there was a misapprehension that the innovation would be highly disruptive for the hyperscalers.
He believes that the opposite has happened and that infrastructure has become a lot cheaper, with investors likely to get the money they have spent on capital expenditure, as well as a better return.
For this article, we selected AI stocks by going through news articles, stock analysis, and press releases. These stocks are also popular among hedge funds. The hedge fund data is as of Q4 2024.
Why are we interested in the stocks that hedge funds pile into? The reason is simple: our research has shown that we can outperform the market by imitating the top stock picks of the best hedge funds. Our quarterly newsletter’s strategy selects 14 small-cap and large-cap stocks every quarter and has returned 373.4% since May 2014, beating its benchmark by 218 percentage points (see more details here).
A view of a motor grader at work, with a highway construction contract beside it.
IGC Pharma, Inc. (NYSEAMERICAN:IGC)
Number of Hedge Fund Holders: 3
IGC Pharma, Inc. (NYSEAMERICAN:IGC) is a pharmaceutical company engaged in developing treatments for Alzheimer’s disease. The company integrates cutting-edge AI technologies into its drug discovery processes. On March 4, IGC Pharma announced that it has advanced its Artificial Intelligence platform with the development of a new AI-driven model. The model aims to improve the diagnosis of Alzheimer’s disease and other causes of dementia. Trained on multi-modal clinical data from leading public research databases, it analyzes neuroimaging biomarkers, cognitive assessments, genetic risk factors, medical history, neurological exams, and demographic information to enable precision in its diagnostic framework. As a result, reliable, personalized insights can be generated across different patient populations.
“The AI model is a potential game changer for our growth strategy. Our AI platform is a key driver of IGC Pharma’s long-term growth strategy, reinforcing our commitment to precision medicine and targeted treatments for neurodegenerative diseases. Misdiagnosis remains a significant challenge, often delaying treatment for patients who need it most. Our AI-driven model aims to close this gap, ultimately improving patient outcomes.”
-Ram Mukunda, CEO of IGC Pharma.
Overall IGC ranks 10th on our list of the AI stocks that are making headlines. While we acknowledge the potential of IGC as an investment, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and doing so within a shorter time frame. If you are looking for an AI stock that is more promising than IGC but that trades at less than 5 times its earnings, check out our report about the cheapest AI stock.
READ NEXT: 20 Best AI Stock To Buy Now and Complete List of All AI Companies Under $2 Billion Market Cap.
Disclosure: None. This article is originally published at Insider Monkey.
